Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-07-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
2022年第一次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening and procedures of the 2022 first extraordinary general meeting (临时股东大会) of 福安药业（集团）股份有限公司. It details the legality of the meeting's notice, attendance, voting procedures, and resolutions passed. It does not contain financial statements or results but focuses on the legal compliance and validity of the shareholder meeting and its resolutions. This type of document is not an Annual Report, Interim Report, or Earnings Release, nor is it a voting result announcement (which would be a formal declaration of vote outcomes). Instead, it is a legal opinion related to a shareholder meeting, which fits best under Regulatory Filings (RNS) as it is a compliance/legal document that does not fit other categories.
2022-07-15 Chinese
关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a senior management personnel (徐鹏) as the company's vice general manager. It details the individual's background, qualifications, and the board's approval of the appointment. There is no financial data, no mention of a report or meeting results, and it is clearly about management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on this announcement, confirming the classification.
2022-07-15 Chinese
第五届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fifth meeting of the fifth board of directors of the company 福安药业（集团）股份有限公司. It details the meeting date, attendance, voting results, and mentions the appointment of senior management and approval of guarantees for subsidiary financing. The content focuses on board decisions and management appointments, with no financial statements or earnings data. It is not a full report but an announcement of board/management decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and specific to board resolutions, confirming this classification.
2022-07-15 Chinese
关于变更监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change in the company's supervisory board (监事), specifically about the resignation of a supervisor and the election of a new one. It mentions the dates of meetings and the election results. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. The document is short and focused solely on this personnel change, with no financial data or other report content.
2022-07-15 Chinese
关于为子公司申请银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company providing a guarantee for its subsidiary's bank credit application. It includes details about the guarantee, the subsidiary's financials, board and independent director opinions, and approvals. The document is relatively short (2378 characters) and focuses on a specific financing guarantee event rather than comprehensive financial results or reports. It does not contain full financial statements or detailed financial analysis. This fits the category of a Capital/Financing Update (CAP), as it relates to financing activities and guarantees provided by the company.
2022-07-15 Chinese
2022年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2022 first extraordinary general meeting (临时股东大会) of 福安药业 (Fuan Pharmaceutical Group). It details the meeting date, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. There is no detailed financial data or comprehensive report content. The document is a formal announcement of voting results from a shareholder meeting, not the meeting materials or the full report itself. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1669 characters), consistent with an announcement rather than a full report.
2022-07-15 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.